PRESS-RELEASE filed Nov 5, 2026 at 07:10 ET
Akebia reported Q3 2026 total revenue of $36.9M, down 37% YoY from $58.8M, driven by a 53% decline in Auryxia revenue ($20.0M vs $42.5M) due to generic competition. Vafseo net product revenue was $14.8M, roughly flat YoY, with patient growth of 140% YoY but revenue impacted by customer inventory reduction and TDAPA expiration concerns. Net loss was $14.4M vs net income of $0.5M a year ago. Cash position remains strong at $159.3M.